A variety of approaches to inhibit TGFβ signaling [12] and glioma recruitment of GAM [13] have failed to show therapeutic efficacy in GBM [12], underscoring the need for refined therapeutic targets. The gene discussed is TGFB1; the disease is glioblastoma.